Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, raised $12 million by offering 1.5 million shares at $8, below the range of $10 to $12. Aldeyra Therapeutics plans to list on the NASDAQ under the symbol ALDX....read more
Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, lowered the proposed number of shares it is offering on its upcoming IPO on Friday. The Burlington, MA-based company now plans to raise $13 million by offering 1...read more
Aldeyra Therapeutics prices IPO at $8, below the range
Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, raised $12 million by offering 1.5 million shares at $8, below the range of $10 to $12. Aldeyra Therapeutics plans to list on the NASDAQ under the symbol ALDX....read more
4 US IPOs planned for the week of Apr 28
The following IPOs are expected to price this week: Aldeyra Therapeutics (ALDX), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to...read more
Rare disease biotech Aldeyra Therapeutics cuts proposed IPO deal size by 47%
Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, lowered the proposed number of shares it is offering on its upcoming IPO on Friday. The Burlington, MA-based company now plans to raise $13 million by offering 1...read more
4 US IPOs planned for the week of Apr 21
The following IPOs are expected to price this week: Aldeyra Therapeutics (ALDX), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to...read more